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ABSTRACT
Background: There is a 3-fold risk of developing end stage kidney disease in Non-Hispanic
African Americans compared to Non-Hispanic White Americans (Centers for Disease Control
and Prevention, 2017). Estimated glomerular filtration rate (eGFR), one of the fundamental
algorithms for coordinating treatment for kidney disease which factors in age, race, gender, and
levels of creatinine, may pose an issue in this vulnerable population. Currently African
Americans receive a correction factor between 1.21 and 1.16 to their eGFR to adjusting the value
higher, potentially impacting appropriate kidney disease classification, and delaying beneficial
interventions (National Kidney Foundation, 2020).
Methods: A systematic literature search of four databases was completed. Eligibility criteria
included 1) published in a peer reviewed journal, 2) English language, 3) the use of race
correction in calculating eGFR, and 4) a quantitative study design. A total of 47 articles were
screened with 17 selected for final review. The Johns-Hopkins Nursing Evidence - Based
Practice evidence guide was then used to rate the strength and quality of the evidence.
Results: Early evidence of the unreliability of race based eGFR equations emerged in 2008, and
the body of evidence continues to grow. Recent studies have found eGFR calculated with no race
corrections correlate best with directly measured iothalmate GFR in black patients (Zelnick et
al., 2021), and that a potential 1,066,026 Black Americans may be reclassified to a more severe
stage of CKD (Bragg-Gresham et al., 2021). Use of the race correction in GFR equations has
been poorly supported in studies conducted in Africa and Brazil. For those with HIV, an accurate
eGFR is doubly important yet all eGFR equations have marked variability. Some medical
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facilities have successfully updated to calculating eGFR without the racial coefficient (Shi et al.,
2021).
Conclusion: Nurses should be aware of the implications of using race correction in eGFR
equations, educate their patients on its use, and advocate for those near threshold targets to
ensure equitable and timely access to appropriate kidney disease interventions.
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INTRODUCTION
The Black Lives Matter movement has inspired social and criminal justice reform
nationwide against lingering discriminatory practices in America. It is long overdue that these
reformations extend to healthcare, as researchers and healthcare workers have a duty to face and
fix systemic racial inequalities in medicine. There are numerous examples of racial health
disparities in the United States. The Coronavirus pandemic has made this glaringly evident, with
people of color experiencing disproportionately higher rates of infection, morbidity, and
mortality (Kullar et al., 2020). In the U.S., a country with one of the highest maternal mortality
rates, non-Hispanic black women have a 3.2 times higher pregnancy-related mortality rate as
compared to White women (Ahn et al., 2020; Petersen et al., 2019). Healthcare professionals
have a moral responsibility to acknowledge and address these disparities in order to minimize
them and promote equitable, quality outcomes for all patients.
In addition to these health disparities, the Center for Disease Control (CDC) (2017)
reports that African Americans are 3 times more likely than Caucasians to develop end-stage
kidney disease (ESKD), formerly called end-stage renal disease. The cause for this inequality is
multifaceted and includes both biologic and social elements (Norton et al., 2016). Genetic
screening has identified variations at the apolipoprotein L1 gene (APOL1) as a possible genetic
component. The mechanism of action between the APOL1 variant and kidney damage remains
unclear. Some researchers report that this genetic variance may account for 70% of the racial
disparity, while Umeukeje & Young (2019) feel that this statistic is premature. The presence of
two APOL1 high-risk variants alone does not cause kidney disease; it is likely that other genetic
and environmental factors modify the expression of this gene to eventually cause kidney damage
(Friedman & Pollak, 2011). Interestingly, the frequency of APOL1 alleles is essentially
1

nonexistent in Ethiopia, thus Americans of Ethiopian descent are not expected to be at high risk
for kidney disease, despite being categorized as African American (Friedman & Pollak, 2011).
Other contributors to this disparity include social conditions such as culture and poverty,
institutional context such as healthcare and legal systems, and individual risk factors such as
tobacco and alcohol use (Umeukeje & Young, 2019). African Americans are also more likely to
have hypertension and diabetes, two major biologic risk factors for developing kidney disease
(CDC, 2017). Underlying social conditions play a big role in this disparity as African Americans
are a disadvantaged group and face contributing issues such as decreased access to healthcare,
psychosocial and socioeconomic disadvantages, and racial biases (Norton et al., 2016).
When analyzing racial disparities in kidney disease, it is important to look at the use of
race-based algorithms in diagnosis and treatment (see Appendix A). Estimated glomerular
filtration rate (eGFR) is a laboratory test commonly used to measure kidney function based on
creatinine. Practitioners use this value for diagnosing kidney disease, staging the severity, and
determining treatment options. A higher eGFR value indicates better kidney function. An eGFR
considered ‘normal’ for an average healthy person is a value of 90 or higher. A value between 60
and 90 for longer than three months may indicate kidney damage, and a value below 60 for
longer than 3 months indicates chronic kidney disease (CKD) (National Kidney Foundation
[NKF], 2020). CKD may progress to ESKD, which will require dialysis or transplantation for
treatment (CDC, 2020).
Since the mid 1920’s creatinine has been used to quantify kidney function, however,
obtaining direct measurements of creatine clearance remains burdensome. Creatinine equations
and assays have been developed to estimate GFR. The Cockcroft-Gault equation was developed
in the 1970’s to estimate kidney function without a lengthy 24-hour urine collection and
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introduced variables for weight and sex. Women received a correction factor of 15% that laid the
groundwork for later race correction factors (Braun et al., 2021). A correction factor is a
mathematical adjustment to a calculation to account for deviations in the sample or correct
systematic error (Farrance & Frenkel, 2012). The Cockcroft-Gault formula is no longer
recommended for clinical use as it gives inaccurate results, and overestimates kidney function by
10-20% (NKF, 2021). In the late 1990’s the Modification of Diet in Renal Disease (MDRD)
equation replaced the Cockcroft-Gault (Braun et al., 2021). The four variables the MDRD
equationconsiders are age, sex, race, and diabetes (Florkowski et al., 2011). The developers of
the equation found black race to be an independent predictor of kidney function, and suggested
the difference was due to racial differences in muscle mass (Levey et al., 1999). However, only
outdated research from 10-20 years prior on racial differences in muscle mass were cited in this
study, and no mention of other factors such as socioeconomic class were considered.
Additionally, the authors used a wide array of measurements of muscle mass and did not offer a
definition of black or white (Braun et al., 2021). The MDRD equation ultimately derived a race
correction of 1.21 for Black patients (Levey et al., 1999). Because the MDRD sampled only
those with kidney disease, the equation has been found to be inaccurate at better levels of kidney
function and near the CKD threshold of 60 1mL/min/1.73 m2 (Stevens et al., 2011), still, more
than 65% of North American laboratories continue to use this equation (Miller & Vassalotti
2020). In 2009 the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) was
developed to account for the shortcomings of the MDRD and is recommended for clinical use
today (NKF, 2021). The CKD-EPI equation reduced the race correction for Blacks from 1.21 to
1.16 and incorporates variables for age and gender (Florkowski et al., 2011). Race, in both the
MDRD and CKD-EPI algorithm is divided into only two categories: African American or Non-
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African American (NKF, 2020). Today, the justification for this correction factor remains as
“higher average muscle mass and creatinine generation rate in African Americans” (NKF, 2020,
p.6). Not only does this justification of increased muscle mass have roots in racism, this
correlation has also been poorly supported in the literature (Braun et al., 2021).
The ramifications of incorrectly increasing eGFR in a population that disproportionately
suffers from kidney disease are severe, potentially delaying earlier, disease appropriate therapies
and pre-emptive transplantation. On the other hand, waiving the correction factor, if correct, has
the potential to over treat patients, or give them medications at a level that is too high for their
kidneys to filter (Hornum & Feldt-Rasmussen, 2017). The use of race has been called into
question for other medical algorithms as well (Vyas et al., 2020). Sociologists argue that race is a
social, and not a biological construct (Williams & Sternthal, 2010). African Americans are not a
homogenous group; they have complex ancestry and diverse genetics (Norton et al., 2016).
Grouping such solely as “African American” may be insufficient to describe a population
(Friedman & Pollak, 2011). Some hospitals, such as Beth Israel Deaconess Medical Center,
Mass General Brigham and the University of Washington, have abandoned the use of race
correction factor in eGFR in light of research highlighting the problematic nature of this
algorithm (Gaffney, 2020). Additional research is needed to investigate the validity of current
practices and evaluate the quality of research behind the recommendations for and against the
use of race in calculating eGFR.
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PROBLEM
Racial health disparities persist around the world. A serious commitment amongst
researchers and medical professionals to minimize these disparities and ensure equitable
outcomes is warranted. One example of a racial health disparity is the 3-fold risk of developing
end stage kidney disease in Non-Hispanic African Americans compared to Non-Hispanic White
Americans (Centers for Disease Control and Prevention, 2017). Estimated glomerular filtration
rate (eGFR), one of the fundamental algorithms for coordinating treatment for kidney disease
which factors in age, race, gender, and levels of creatinine, may pose an issue in this vulnerable
population. African Americans receive a correction factor between 1.21 and 1.16 to their eGFR
based on creatinine levels, adjusting the value higher in a population that disproportionately
suffers from end – stage kidney disease (ESKD) (NKF, 2020). The ongoing debate over the use
of race in calculating eGFR warrants further examination to inform professional nursing practice,
especially nephrology nursing practice, a specialty with no currently published literature
addressing this issue. Ignoring this issue has the potential to delay appropriate treatment and
transplantation in African American patients (Vyas et al., 2020).
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PURPOSE
The purpose of this project is to systematically appraise the quality of research that
argues for or against the use of the eGFR correction factor and integrate findings into a cohesive
literature review. Despite growing conversations in the medical community, there is currently no
published literature on this debate within the discipline of nursing. As the most trusted profession
(Saad, 2020), nurses have a duty to be aware of health disparities and advocate for their patients.
This literature review will educate nurses on the implications of incorporating race into
estimating kidney function and how it may exacerbate racial kidney disease disparities.
Additionally, this review may potentially spark conversations about other areas of nursing
practice that are outdated or inadvertently perpetuate inequitable care.
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METHODS
The literature review was conducted over 4 databases including PUBMED, CINAHL,
JSTOR, and Cochrane Library. The following search terms were used to identify relevant
articles:
•

eGFR or 'estimated GFR' or 'glomerular filtration rate'

•

AND African American or black American or black

•

AND 'race coefficient' or 'race multiplier' or 'race correction'

After duplicates were removed from the results, each article was screened for eligibility by
reviewing the abstract. Eligibility criteria include (1) published in a peer reviewed journal (2)
English language (3) included use of the African American race correction in calculating eGFR
and (4) quantitative research methods. Articles that met inclusion criteria received a full text
review and appraisal. The articles selected for final review were appraised for the strength (Level
I-V) and quality of evidence (A, B, C) using the Johns-Hopkins Nursing Evidence-Based
Practice evidence level and quality guide (see Appendix B) (Dang & Dearholt, 2017). Seventeen
articles were appraised and summarized in Appendix B
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RESULTS
Of the 24 relevant articles, 17 met criteria for final synthesis. Selected studies all
employed quantitative methods using a variety of designs, including validation studies, crosssectional studies of existing de-identified data, retrospective studies, and prospective cohort
studies. All were graded as evidence Level III per the Johns Hopkins Evidence-Based Nursing
Model. Quality ratings ranged from A-C. The largest sample size was 786,718 and the smallest
was 64. Countries involved in studies included USA, Brazil. Nigeria, Kenya, and Thailand. The
earliest study was published in 2008 and the most recent was published in 2021.
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DISCUSSION
While the argument against race based GFR has recently gained more traction (Gaffney,
2020), studies published as early as 2008 raised concerns about eGFR limitations and variability.
In an early study conducted in the Department of Defense medical system, eGFR was calculated
using the MDRD equation to explore the association between race and compliance with selected
CKD quality outcome targets and determine if equitable care was achieved in a system without
financial barriers. However, in this medical system a race correction factor was not automatically
incorporated, and providers were reminded by a message box to manually multiply the result by
a factor of 1.18. Provider adherence to this step was not assessed. While this study found that
Black and White patients with CKD stage 3 and 4 met most compliance targets similarly , there
was a potential confounding variable if providers were not uniformly applying the race
correction to Black patients. This study demonstrated that equitable access to healthcare may
overcome CKD disparities; it also presents an example of confounding research results when
eGFR corrections are not applied in a standardized manner. Additionally, the authors bring up
concerns about limitations of the MDRD acknowledging the complexity of race as a construct
that frequently exceeds the boundaries of the dichotomous race category (Black; yes/no) used in
the MDRD equation (Gao et al., 2008). Kramer et al. (2008) found that three eGFR equations the MDRD, Cystatin-C with no gender or race correction, and Cystatin-C with gender and race
correction all had significant variability when estimating CKD prevalence across racial and
ethnic groups, especially in women, and suggested more research into the accuracy of eGFR
equations was needed. Two years later Peralta et al. (2010) found that the MDRD and CKD-EPI
equations with race corrections “may lead to a systematic misclassification of CKD in young
blacks” (p. 3938), as Black men with a GFR above the CKD threshold still had a 2.5-fold higher
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prevalence of CKD risk factors when compared to Whites, and thus were likely being
misclassified as CKD free.
Evidence against eGFR race correction factors continued to emerge. An analysis of 1342
patients with CKD found no significant difference in the creatinine clearance to GFR ratio
among different races or ethnicities (Lin et al., 2013). In an analysis of the CKD-EPI equation
with and without race correction, CKD-EPI with the race correction overestimated iGFR by
3.1mL/min/1.73 m2 (95% CI, 2.2-3.9 mL/min/1.73 m2; P < .001), while omitting the race
correction underestimated iGFR by a smaller magnitude. Additionally, for Black participants, the
equation with the strongest correlation with iGFR was the CKD-EPI equation without race
correction (r=0.75) (Zelnick et al., 2021). After investigating a proposed four level CKD-EPI
equation (Black, Asian, Native American and Hispanic, and White) to replace the standard twolevel variable (Black, White and other) race correction, Stevens et al. (2011) did not recommend
the four-level equation, as it was more accurate in some, but not all populations. They found that
the two-level CKD-EPI equation performed well for Blacks in the USA and Europe with a GFR
< 90mL/min per 1.73m2, but poorly in the South African cohort, where eGFR performance was
best with no race correction at all. These findings were converse to the study by Omuse et al.
(2017) who studied subjectively healthy Black Africans. In their comparison of several equations
for estimating GFR, including full age spectrum, Cockroft-Gault, and CDK-EPI and MDRD with
and without the race corrections, CDK-EPI with the race correction ultimately performed the best
as it accurately classified 93.6% of its healthy participants in a GFR as stage 1 CKD. However,
Omuse et al. (2017) had no direct GFR measurement for comparison nor were urine samples for
hematuria or proteinuria collected.
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Discourse and disagreement on the accuracy of eGFR equations has been found to be
global problem amongst multiple ethnicities. In Brazil, two validation studies (Veronese et al.,
2014; Zanocco et al., 2012) failed to show an improvement in accuracy with the use of race
correction in the CKD-EPI equation, thus Barreto et al. (2016) did not use race correction in their
estimation of prevalence and disparity in CKD in Brazil. Haas Pizarro et al. (2020) found that
when recalculating eGFR using the CKD-EPI equation with race correction in patients with CKD
and a genomic ancestry > 50% African, 13 out of 23 patients were falsely reclassified to a
normal renal function. In Asian countries, Japanese and Chinese race corrections for eGFR have
also been derived for use in the MDRD equation. Praditpornsilpa et al. (2011) found the MDRD
and CKD-EPI to have levels of disagreement at 9.6 mL/min per 1.73m2 and 8.0 mL/min per
1.73m2, respectively, and recommended validation of the MDRD equation in each specific ethnic
population.
Accurate measurement of GFR in patients with Human Immunodeficiency Virus (HIV) is
essential, as this group is vulnerable to CKD and ESKD due to medication dosages of
antiretroviral therapy (ART)being dependent on kidney function. A study of 99 HIV-infected
and ART naïve Kenyan adults found that the CKD-EPI performed the best compared to directly
measured iGFR (R2=23) and showed modest improvements in bias and accuracy with removal of
race correction (85% of estimates within 30% of measured GFR) (Wyatt et al., 2013). To
investigate this population in America, Anker et al. (2016) sampled 21,905 treatment naïve HIVinfected Black veterans through the Department of Veterans Affairs HIV Clinical Case Registry.
They found that those reclassified to an eGFR <60 mL/min per 1.73m2 after calculating eGFR
without race correction had a higher incidence of CKD risk factors, when compared to Whites.
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This finding is likely indicative of a misclassification under the MDRD formula, similar to the
findings of Peralta et al. (2010) in healthy Black Americans.
The ramifications of abandoning the race correction are immense. Bragg-Gresham et al.
(2021) estimate that removing the race correction would reclassify an estimated 1,066,027 Black
adults in the United States, to CKD stage 3 or more severe. A study using data from two large
medical centers found that 33.4% of their sample of 2225 would hypothetically be reclassified to
a more severe CKD stage if the race correction was removed. Importantly, this study also found
that none of the patients reclassified to meet the kidney transplant threshold without the race
correction were referred, evaluated, or waitlisted for transplant (Ahmed et al., 2021). This
coincides with a study by Zelnick et al. (2020), who found a use of eGFR with race correction
factors was associated with a 35% (95% CI, 29%-41%) higher risk of achieving an eGFR less
than 20 mL/min/1.73 m2 and a potential transplant delay of 1.9 years in their sample of 1658
Black patients. Lastly, drug dosages are impacted by estimates of renal function. Two
pharmacists found that CKD-EPI without race correction was less biased and more precise than
CKD-EPI with race correction (median difference 4.3 [IQR = 9.8] mL/min vs 15.1 [IQR= 19.7]
mL/min; P < 0.0001). CKD-EPI without race correction also had a higher level of agreement
with dosing by creatinine clearance (CrCl; κ = 0.779) and was the authors ultimate
recommendation when guiding drug dosing by creatinine clearance (Miller & Knorr, 2021).
Successful steps have been taken to remove race correction from GFR calculations in the
U.S. The University of Washington Medicine System moved from MDRD to CKD-EPI with no
race correction on May 29th, 2020 (Hong, 2020; Shi et al., 2021). Before the switch, it was the
providers choice whether to include a race correction. Shi et al. (2021) studied the impact of the
change at the University of Washington Medical Center and found that the change in use from
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the MDRD to CKD-EPI with no race correction resulted in 3.5% of all patients reclassified to a
worse kidney function (N=241,760). They also found fewer patients overall with an eGFR <60
mL/min per 1.73m2, demonstrating that the switch did not cause an overwhelming increase in
nephrology referrals.
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LIMITATIONS
The principal limitation in this review was the use of variable methods to validate eGFR
equations. While some studies compared to direct measure of GFR such as iothalamate clearance
(iGFR) (Zelnick et al., 2021; Wyatt et al., 2013), others created their own model (Anker et al.,
2016; Peralta et al., 2010), used other measurements such as urine microalbumin (Barreto et al.,
2016; Lin et al., 2013), GFR mean (Stevens et al., 2011) or had no direct measure for comparison
(Abefe et al., 2009; Bragg-Gresham et al., 2021; Haas Pizarro et al., 2020; Kramer et al., 2008;
Omuse et al., 2017) The second limitation was the complexity of statistical analyses performed
in each of the studies. As a novice researcher, the depth of the review was based on the author’s
understanding of the literature.
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CONCLUSION
Substantial evidence against the need for race correction of eGFR equations continues to
emerge in the literature. Some facilities in the U.S. have already started to move away from race
- based MDRD and CKD-EPI equations (Gaffney, 2020; Shi et al., 2021). Both early and recent
research has identified inaccuracies in eGFR equations. Additionally, the race correction has
been poorly validated for accuracy in other countries, including Brazil (Barreto et al., 2016; Haas
Pizarro et al., 2020) and South Africa (Stevens et al., 2011). For patients with HIV, accurate
classification of kidney function is key to dosing of medications necessary for their survival, yet
Blacks with HIV are likely overestimated in their kidney function (Anker et al., 2016; Wyatt et
al., 2013). To guide drug dosages, CKD-EPI without race correction performed the best (Miller
& Knorr, 2021).
In addition to the quantitative research, sociologic arguments have emerged. Braun et al.
(2021) found that in a literature review of research on GFR comparisons between Black and
White persons with CKD, the majority (28 out of 38) offer no explanation for the racial
difference demonstrating that muscle mass as an innate difference has become a “fact” with no
need for explicit restating. Eneanya et al. (2019) explained that using race for clinical decision
making “is justified only if (1) the use confers substantial benefit; (2) the benefit cannot be
achieved through other feasible approaches; (3) patients who reject race categorization are
accommodated fairly; and (4) the use of race is transparent” (p. 114). In response to these
criteria, Levey et al. (2020) propose continuation of the use of race correction with full
disclosure to patients, and mindful use of Cystatin-C as a confirmatory test.
The implications of these findings for professional nursing practice warrant education
and advocacy. An understanding of culture, socioeconomic factors, and the consequences of
16

treating racial groups as a homogenous population is paramount to combatting disparities
(Pearson, 2008). Nephrology nurses especially should be aware of the racial disparities in CKD
and how current eGFR race corrections may exacerbate them. Black patients with poor kidney
function and patients with HIV are especially vulnerable populations for overestimating kidney
function. Nephrology nurses should take notice of patients who are near thresholds such as
below 60 mL/min per 1.73m2 for diagnosis of CKD or near 20 mL/min per 1.73m2 for transplant
qualification, and advocate for other confirmatory diagnostic tests. Nurses may also wish to
inform patients if the correction is being used and educate them on its purpose and implications
to increase transparency and meet the criteria proposed by Eneanya et al. (2019). Lastly,
depending upon the eGFR equation being used, there is potential for under or overestimating
drug dosages; nurses should vigilant to monitor for adverse effects from medication.
More research on this topic is warranted as the methods used to validate and compare
eGFR equations varied across studies. In addition, confirmatory studies on drug dosages, using
consistent measures of GFR for comparison and conducted in a variety of populations are
needed. The National Kidney Foundation – American Society of Nephrology task force is
actively working to determine and approach to address this issue and construct recommendations
on how to proceed and to standardize care (Delgado et al., 2021).
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APPENDIX A: EGFR EQUATIONS
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eGFR Equations
Cockcroft-Gault:
CCr={((l 40–age) x weight)/(72xSCr)}x 0.85 (if female)

4 Variable MDRD:
186 x [Plasma Creatinine (μmol/L) x 0.0011312] -1.154 x [age (years)] -0.203 x [0.742 if female] x
[1.212 if black]

CKD-EPI eGFR:
Female with Creatinine < 62 μmol/L; use eGFR = 144 x (Cr/61.6)-0.329 x (0.993)Age
Female with Creatinine > 62 μmol/L; use eGFR = 144 x (Cr/61.6)-1.209 x (0.993)Age
Male with Creatinine < 80 μmol/L; use eGFR = 141 x (Cr/79.2)-0.411 x (0.993)Age
Male with Creatinine > 80 μmol/L; use eGFR = 141 x (Cr/79.2)-1.209 x (0.993)Age

where Cr is the plasma creatinine (μmol/L) and CCr is the creatinine clearance (mL/minute)

(Florkowski et al., 2011; NKF, 2021)
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APPENDIX B: JOHN HOPKINS NURSING EVIDENCE-BASED RESEARCH
EVIDENCE APPRAISAL
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Evidence and Quality Rating adapted from Dang & Dearholt (2017)
Evidence Levels
Level I
Experimental study, randomized
controlled trial (RCT)
Explanatory mixed method
design that includes only a level I
quaNtitative study
Systematic review of RCTs, with or
without meta- analysis

Level II
Quasi-experimental study
Explanatory mixed method
design that includes only a level II
quaNtitative study
Systematic review of a combination
of RCTs and quasi-experimental
studies, or quasi- experimental
studies only, with or without metaanalysis

Level III
Nonexperimental study

Systematic review of a combination
of RCTs, quasi-experimental and
nonexperimental studies, or
nonexperimental studies only, with
or without meta-analysis
Exploratory, convergent, or
multiphasic mixed methods
studies
Explanatory mixed method design
that includes only a level III
quaNtitative study
QuaLitative study Meta-synthesis

Quality Ratings
QuaNtitative Studies
A High quality: Consistent, generalizable results; sufficient sample size
for the study design; adequate control; definitive conclusions; consistent
recommendations based on comprehensive literature review that includes
thorough reference to scientific evidence.
B Good quality: Reasonably consistent results; sufficient sample size
for the study design; some control, fairly definitive conclusions;
reasonably consistent recommendations based on fairly comprehensive
literature review that includes some reference to scientific evidence.
C Low quality or major flaws: Little evidence with inconsistent
results; insufficient sample size for the study design; conclusions
cannot be drawn.

QuaLitative Studies
No commonly agreed-on principles exist for judging the quality of
quaLitative studies. It is a subjective process based on the extent to which
study data contributes to synthesis and how much information is known
about the researchers’ efforts to meet the appraisal criteria.

For meta-synthesis, there is preliminary agreement that quality
assessments of individual studies should be made before synthesis to
screen out poor-quality studies1.
A/B High/Good quality is used for single studies and meta-syntheses2.
The report discusses efforts to enhance or evaluate the quality of
the data and the overall inquiry in sufficient detail; and it
describes the specific techniques used to enhance the quality of
the inquiry. Evidence of some or all of the following is found in
the report:
• Transparency: Describes how information was documented
to justify decisions, how data were reviewed by others, and
how themes and categories were formulated.
• Diligence: Reads and rereads data to check interpretations;
seeks opportunity to find multiple sources to corroborate
evidence.
• Verification: The process of checking, confirming, and ensuring
methodologic coherence.
• Self-reflection and scrutiny: Being continuously
aware of how a researcher’s experiences, background,
or prejudices might shape and bias analysis and
interpretations.
• Participant-driven inquiry: Participants shape the scope and
breadth of questions; analysis and interpretation give voice
to those who participated.
• Insightful interpretation: Data and knowledge are linked in
meaningful ways to relevant literature.
C Low quality studies contribute little to the overall review of findings
and have few, if any, of the features listed for high/good quality.
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Evidence Levels
Level IV
Opinion of respected
authorities and/or nationally
recognized expert
committees or consensus
panels based on scientific
evidence
Includes:

• Clinical practice guidelines
• Consensus panels/position
statements

Quality Ratings
A High quality: Material officially sponsored by a professional, public, or

private organization or a government agency; documentation of a
systematic literature search strategy; consistent results with sufficient
numbers of well-designed studies; criteria-based evaluation of overall
scientific strength and quality of included studies and definitive
conclusions; national expertise clearly evident; developed or revised
within the past five years
B Good quality: Material officially sponsored by a professional, public, or

private organization or a government agency; reasonably thorough and
appropriate systematic literature search strategy; reasonably consistent
results, sufficient numbers of well-designed studies; evaluation of
strengths and limitations of included studies with fairly definitive
conclusions; national expertise clearly evident; developed or revised
within the past five years
C Low quality or major flaws: Material not sponsored by an official

organization or agency; undefined, poorly defined, or limited literature
search strategy; no evaluation of strengths and limitations of included
studies, insufficient evidence with inconsistent results, conclusions cannot
be drawn; not revised within the past five years

Level V
Based on experiential and
nonresearch evidence Includes:
• Integrative reviews
• Literature reviews
• Quality improvement,
program, or financial
evaluation

• Case reports
• Opinion of nationally
recognized expert(s)
based on experiential
evidence

Organizational Experience (quality improvement, program or
financial evaluation)
A High quality: Clear aims and objectives; consistent results

across multiple settings; formal quality improvement,
financial, or program evaluation methods used; definitive
conclusions; consistent recommendations with thorough
reference to scientific evidence
B Good quality: Clear aims and objectives; consistent results in a single

setting; formal quality improvement, financial, or program evaluation
methods used; reasonably consistent recommendations with some
reference to scientific evidence
C Low quality or major flaws: Unclear or missing aims and objectives;

inconsistent results; poorly defined quality improvement, financial, or
program evaluation methods; recommendations cannot be made

Integrative Review, Literature Review, Expert Opinion, Case
Report, Community Standard, Clinician Experience, Consumer
Preference
A High quality: Expertise is clearly evident; draws definitive

conclusions; provides scientific rationale; thought leader(s) in the field
B Good quality: Expertise appears to be credible; draws fairly definitive
conclusions; provides logical argument for opinions

C Low quality or major flaws: Expertise is not discernable or is dubious;
conclusions cannot be drawn

22

APPENDIX C: TABLE OF EVIDENCE

23

Summary Table of Research Literature on eGFR Race Correction
Design
Sample /
Author /
Aim / Objective
eGFR
Settings
Year
Equation(s)
Abefe et
al. (2009)

Secondary
analysis of a
previous
quantitative
study

Ahmed et Cross-sectional
al., (2021) study

32 healthy
Nigerians and 34
Nigerian patients
with CKD; serum
creatinine
consistently above
177 [micro]mol/L,
passing at least
500 ml of
urine/24hrs. and
not previously
dialyzed.

To examine the
usefulness of 6
eGFR formulas
in an African
population to
measured
creatinine
clearance

CockroftGault
MDRD
Jeliffe
Mawer
Hull
Gates

Key Findings
All predictive formulas
correlated significantly
with creatinine clearance
in CKD subjects and
controls.

JHEBN

Level: III
CockroftGault may be
Quality: B
best for
homogenous
African Black
populations

Cockroft-Gault
outperformed MDRD and
had the least variance
(6.3% vs. 16.3%) and
highest accuracy (49.3%
vs 9.9%)

Cockroft-Gault had the
highest r2 of 0.94
743 of 2225 African
N = 2225 selfTo examine the CKD-EPI
with
/
without
American patients would
reported African impact of the
be reclassified to a more
race
Americans
race multiplier
severe CKD stage with no
correction
for African
race correction
Two large
Americans in the
academic medical CKD-EPI eGFR
64 of 2069 African
centers and
equation on
American patients would
affiliated
CKD
be reassigned
community
classification and
To meet transplant
primary care and care delivery.
requirements with no race
specialty
multiplier, yet 0 of these
practices.
64 were referred,
evaluated, or waitlisted
for kidney transplant
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Implications
for Practice

Informing
Level: III
patients on
whether the
Quality: B
race correction
is being used
on them
Advocating for
borderline
patients on the
transplant
threshold

Design
Author /
Year
Anker et al. Retrospective
cohort study
(2016)
patients

Sample / Settings Aim / Objective
N=21,905
treatment naïve
HIV-infected
veterans in the
VA health system
Used HIV
Clinical Case
Registry

eGFR
Equation(s)
MDRD with/
without race
correction

Key Findings

Investigate
Persons with eGFR
whether eGFR
<45 mL/min/1.73m2
equations in
had a higher risk of
clinical use might
death compared with
systematically
those with eGFR >80
over-estimate the CKD-EPI
with/without race mL/min/1.73m2
kidney function
among both Blacks
misclassifying the correction
and Whites, but the
CKD status of
association
Black Americans
appeared to be
with HIV
stronger in Blacks.
Compared
removing race
coefficient from
equations on
comparisons
between
Black/White
veterans.

Blacks with eGFR 4560 mL/min/1.73m2
also had a higher risk
of death but
Whites did not.
Racial
differences were
substantially
attenuated when eGFR
was re-calculated
without the race
coefficient

Since no gold
standard
measurements
were available,
outcomes
measured were
all-cause
mortality since
CKD is strongly
associated with
death of HIV
25

Implications for
Practice
eGFR without
race coefficient
may be more
appropriate for
Blacks with HIV

JHEBN

Level:
III
Quality:
B

Author /
Year
Barreto et
al. (2016)

Design
Secondary
analysis of a
longitudinal,
multicenter
cohort study.

Sample / Settings Aim / Objective
Public sector
employees
enrolled in the
Brazilian
Longitudinal
Study of Adult
Health cohort
N= 14,636

Determine
prevalence and
disparities in
CKD in Brazil
Measured eGFR
without the race
correction factor,
and urinary
albumincreatinine ratio

eGFR
Equation(s)

Key Findings

CKD-EPI withoutHigh albumin correction for
creatinine ratio (ACR)
race
or low eGFR was
higher in individuals
of low socioeconomic
status, black and
indigenous
individuals.

Implications for JHEBN
Practice
Level:
Racial and socio- III
economic CKD
disparities found Quality:
in other countries B
as well

CKD-EPI without
correction for
race was justified
Marked discrepancies in this
experimental
in the increases in
design
reduced eGFR and
high ACRs with age
and race.
The combination of
higher prevalence of
CKD in black and
indigenous individuals
could not be explained
by socioeconomic and
health risk factors.
Differences most
likely explained by
health inequalities
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Author /
Year

Design

BraggGresham et
al.
(2021)

Crosssectional study
/ secondary
analysis of deidentified
NHANES data
from surveys
between 19992018

Sample / Settings Aim / Objective
N = 9682 selfreported Black
adults from the
National Health
and Nutrition
Examination
Study
(representative of
US population)

To assess
how much
removing the race
coefficient would
affect the
distribution of
eGFR categories
below
eGFR of 60
mL/min/1.73 m2
both the US
general
population and
the population of
US veterans who
use the Veterans
Affairs (VA)
Health System.

eGFR
Equation(s)
CKD-EPI with /
without
correction for
race

Key Findings
The mean eGFR
decreased from 102.8
mL/min/1.73m2 to
88.1 mL/min/1.73m2
using the CKD-EPI
equation without the
race coefficient in the
US adult black
population.
The mean eGFR
decreased from 82.9
mL/min/1.73 m2 to
71.6 mL/min/1.73 m2
without the race
coefficient in black
US veterans.
Elimination of the race
coefficient would
result in 981,038 more
Black adults in the
US, and an additional
84,988 Black adults in
the VA health system
being classified as
having CKD
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Implications for JHEBN
Practice
Substantial
increase in
estimated
prevalence of
CKD with
elimination of the
race coefficient.

Level:
III
Quality:
B

Author /
Year
Gao et al.
(2008)

Design
Retrospective
cohort study
Association
between race
and
compliance
with selected
Kidney
Disease
Outcomes
Quality
Initiative CKD
recommended
targets in the
Department of
Defense
medical
system

Sample / Settings Aim / Objective
N=8318
Patients with
CKD stage 3 or
stage 4 who
receive free
medical care as
beneficiaries of
the Department of
Defense medical
system

Determine if care
is equitable
between Blacks
and Whites with
CKD in the
Department of
Defense medical
system

eGFR
Equation(s)
MDRD 5variable formula
requiring manual
correction for
Black race by the
provider
(Provider
adherence not
assessed)

Key Findings

Implications for JHEBN
Practice

Provider education Level:
III
on eGFR
limitations
Quality:
Unknown provider B
compliance with
race correction in
Blacks were referred some medical
to nephrology
systems
equitably compared
Black coefficient to Whites
Improvement in
= 1.18
CKD disparity
Provider compliance with access to
with CKD stage 3
healthcare
and 4 targets was not
significantly lower
reliance primarily
for Blacks that
on serum
Whites with the
creatinine level
exception of LDL.
may be
advantageous for
Patients categorized Blacks, both in
as “other” race were comparison to
less likely to achieve Whites and to
targets than Whites. other races,
especially patients
whose serum
creatinine levels
were relatively
low compared
with their true
GFR.
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Compliance with
LDL cholesterol
monitoring was the
only significant
difference between
White and Black

Author /
Year
Haas
Pizarro et
al.
(2020)

Design
Crosssectional,
muti-center
study

Sample / Settings Aim / Objective
To compare, in
patients with
type 1 diabetes,
85 Brazilian
the eGFR
patients with
genomic ancestry calculated without
the use of the
>50% African
correction factor,
with the values
Cohort all had
obtained using
type 1 diabetes
the correction
CKD defined as factor in patients
eGRF , 60ml/min. presenting 50% or
more of African
genomic ancestry.
N=85

eGFR
Equation(s)
CKD-EPI with /
without race
correction

Key Findings

Implications for
Practice
CKD was present in Genomic ancestry
23 patients and
may be a better
56.5% of them were tool than selfredefined as having reporting race
normal renal function when determining
after using the
use of race
correction factor
coefficients.
Genomic Ancestry
did not match selfreported race
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JHEBN

Level:
III
Quality:
C

Author /
Year
Kramer
et al.
(2008)

Design

Sample /
Settings
Population -based N= 6747
study;
Sample from
descriptive/compa Multi-Ethnic
rative
Study of
Atherosclerosis
cohort, but who
do not have
clinical
cardiovascular
disease, ages
45-85.

Aim / Objective eGFR Equation(s) Key Findings

Implications
for Practice

JHEBN

4 variable MDRD

More
investigation
needed to
determine
accuracy of
eGFR,
especially in
racially
diverse
populations

Level: III

Comparison of
prevalence
estimates of CKD
among
gender and
racial/ethnic
groups using
three different
GFR
prediction
equations

Women: CKD
prevalence estimates
varied across
Cystatin C with /
without gender and equations; however,
were more congruent
race coefficient
with the use of
Cystatin C-based
equation without the
use of coefficients.
Men: CKD
prevalence estimates
differed significantly
with the Cystatin C
formula which
incorporates gender
and race coefficients.

CKD prevalence
estimates vary across
racial/ethnic groups,
and the degree of
variability depends
on the
method used to
estimate GFR,
especially among
women.
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Quality:
A

Author /
Year
Lin et al.
(2013)

Miller &
Knorr
(2021)

Design

Sample /
Settings

Aim / Objective

eGFR Equation(s)

Key Findings

Crosssectional /
secondary
analysis of
data from the
Chronic Renal
Insufficiency
Cohort
(CRIC)

CrCl/iGFR ratio
Determine
whether higher
N=1342 chronic levels of
kidney disease albuminuria
patients with
would be
baseline
associated with
measures of
higher, and being
iGFR and 24 – non-Hispanic
hour urine
Black with lower,
collections
CrCl/GFR ratio.

There was no
association between
race/ethnicity and
CrCl/iGFR ratio.

Retrospective
study

N = 210
n = 177 Black
patients
n = 33 White
patients

To determine the
impact of
removing the race
coefficient on
drug dosing in
Black patients in
comparison to
Hospitalized
conventional
patients who
were prescribed methods.
an antimicrobial
that includes
renal dosage
recommendatio
ns in the
product
labeling.

18% rate of discordance
when GFR was
estimated with race
coefficient vs. without.
GFR without race had a
higher level of
agreement with dosing
by creatine clearance.

Deindexed CKD-EPI
using Body Surface
Area and no race
correction
CKD-EPI with race
correction
Cockroft-Gault

No indication of
differences between
Black and Whites in
tubular secretion of
creatinine

Deindexed CKD-EPI
without Race had a
higher level of
agreement
and less drug dose
discordance than CKDEPI with race
coefficients, in
comparison to CrCl
estimates.
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Implications JHEBN
for Practice
This study
does not
confirm the
need for race
correction
factors

Level:
III

Deindexed
CKD-EPI
without race
correction
should be
considered for
guiding drug
dosages

Level:
III

Quality:
B

Quality:
B

Design
Author /
Sample /
Year
Settings
Omuse et al, Secondary
Subjectively
analysis of data healthy Kenyan
(2017)
obtained in a adults with no
global reference symptoms of
interval study. kidney disease
from the
Committee of
Reference
intervals and
Decision Limits
study
N=533

Aim / Objective
Determine the
proportion of
asymptomatic
Black Africans
with reduced
eGFR using four
different
equations
Comparison of
the association
between known
risk factors for
CKD and eGFR
using these
equations

eGFR Equation(s)

Implications
for Practice
4 -v MDRD with /
The 4v–MDRD equation CKD-EPI
without correction for without
with race
race
correction
correction for race
may be the
classified the least
most accurate
number of participants
Cockcroft -Gault
eGFR
(61.7%) as having an
equation in
eGFR equivalent to CKD healthy Black
Full Age Spectrum
stage G1
Africans
Serum creatinine CKDEPI with/without race
and gender coefficients CKD-EPI with race
correction performed the
best in their population,
and MDRD performed
the worst
Key Findings

Only age had a
statistically significant
linear association with
eGFR across all
equations after
performing multiple
regression analysis
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JHEBN

Level:
III
Quality:
C

Author /
Year
Peralta et al.
(2010)

Design

Sample /
Settings
Secondary
N = 3501
analysis of data
healthy young
from the Coronary adults
(black/white);
Artery Risk
Development in
ages 18-30
living in
Young Adults
(CARDIA) cohort Birmingham,
AL, Chicago,
study.
IL,
Minneapolis,
MN, and
Oakland, CA

Aim / Objective
Study the
prevalence of
CKD in a young,
healthy, bi-racial
cohort using the
MDRD
and the CKD-EPI
equations; and
evaluate the
impact of the race
correction
coefficients on
CKD
classification by
race.
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eGFR
Equation(s)
MDRD = 1.21

Key Findings

Using the MDRD
equation,
CKD-EPI = 1.16 prevalence of CKD
stages 4 and 5 was
CARDIA derived higher for Blacks
race coefficient = compared with
1.12
Whites, yet Whites
had a higher
prevalence of CKD
stages 3 and above.

Implications for JHEBN
Practice
CKD
classification
among young
Blacks is
very sensitive to
the race
coefficients.

Despite Whites
having
higher rates of
Prevalence of CKD CKD stage 3,
was similar for
Blacks with
Blacks and Whites eGFRs just above
using CKD-EPI
the CKD
equation
threshold had
higher rates of
Among persons
CKD risk factors
with close to the
threshold of stake 3 Current equations
CKD, Blacks had
used to define
higher incidence of CKD may
CKD risk factors
systematically
miss a high-risk
group of Blacks at
a crucial time in
the disease process
where
interventions may
be beneficial.

Level:
III
Quality:
B

Author / Year

Design

Praditpornsilpa et eGRF equation
validation study
al. (2011)

Sample /
Settings
N = 350
Thai adults
with CKD

Aim / Objective eGFR Equation(s)
Validate the
Japanese and
Chinese CKDEPI and MDRD
equation in Thai
populations

MDRD
MDRD with Thai
variable
CKD-EPI
Chinese equation

Key Findings

Implications
for Practice
Derived an adjustment Each population
of 1.129 in MDRD
should validate
equation for Thais
eGFR equations
before applying
MDRD had a
the equation in
disagreement with
epidemiologic
measured GFR of 9.6 studies or
mL/min/1.73 m2
clinical use.

Japanese equation

CKD-EPI was 8.0 mL/
min/1.73 m2

Reference for
GFR: 99mTcDTPA plasma
clearance

Japanese was 1.9
mL/min/1.73 m2
Chinese was 20.9
mL/min/1.73 m2
Race/ethnic
differences can
significant impact
results obtained using
the MDRD-based
eGFR equation.
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JHEBN

Level:
III
Quality:
B

Author /
Year
Shi et al.
(2021)

Design

Sample /
Settings
Retrospective N=241,760
analysis of
serum
96% of
creatinine and samples from
eGFR values outpatient and
calculated by emergency
department
the various
formulas over visits
20.5-month
period

Aim /
Objective
To evaluate the
impact on our
patient
population
upon adoption
of the
CKD-EPI
equation and
the removal of
the race
correction
factor from the
equation after
previously
using MDRD

eGFR Equation(s)
4 variable MDRD
CKD-EPI
with/without race
correction

Key Findings
3.5% of all patients,
including 4.29% of blacks
were reclassified to
categorically have worse
kidney function when
changing from MDRD to
CKD-EPIno race

Successful
example of
medical
system
switching from
eGFR
equations that
incorporate
Distributions of creatinine race, to CKDand eGFR calculated with EPI with no
CKD-EPI with no race
race correction
correction were not
meaningfully different in Lower referral
Black and
rate to
non-Black patients.
nephrology
Overall number of those
with eGFR under
threshold for nephrology
referral decreased by 2%
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Implications JHEBN
for Practice
Level:
III
Quality:
B

Design
Author /
Year
Stevens Validation study
et al.
Four-level
(2011)
CKD-EPI racial
coefficients were
developed from
N=8254 then tested
for external
validation of
N=3036

Sample /
Settings
External
validation:
Worldwide
databases used
n= 1022 from
United States
and Europe
n=675 from
China
n=248 from
Japan
and n=99 from
South Africa

Implications JHEBN
for Practice
Two-level CKD- The four-level race
Level:
CKD-EPI
Explore the
III
performance of a EPI:
appropriate
equation that was
White coefficient developed for the study
CKD-EPI twofor United
=1
Quality:
level race
was more accurate than the States and
Black
coefficient
=
equation (Black
CKD-EPI (two-level race- Europe with A
or White / Other), 1.157
the
equation in some but not
and CKD-EPI
understanding
Four-level CKD- all populations.
four-level race
that there is
equation (Black, EPI:
likely
White coefficient In South Africa, both the
Asian, Native
variation in
=1
American,
two and four level race
the accuracy
Black coefficient = equations performed
Hispanic)
of GFR
1.160
worse, and performance
estimates
Native American was better when no
among and
and Hispanic =
coefficient
was
used
within racial
1.010
and ethnic
Asian = 1.052
Minimal bias in two-level groups
race equation, except for
Asians
Aim / Objective

eGFR Equation(s)

Key Findings

A four variable CKD-EPI
is not accurate enough to
be implemented in clinical
practice.
Racial differences in
creatinine-based estimating
equations likely reflect
geographic and ethnic
differences rather than race
alone.
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Design
Author /
Year
Wyatt et GFR equations
al.
compared against a
(2013)
direct measure of
GFR by iohexol
clearance.
Iohexol clearance
was calculated using
dried blood spots on
filters, an approach
for areas with low
resources such as
Africa

Sample /
Settings
N=99
HIV positive,
antiretroviral
therapy naïve
Kenyan adults

Key Findings
eGFR
Equation(s)
Determine which Cockcroft-Gault CKD-EPI had the highest
calculation of
accuracy, and bias and
eGFR has the
4 variable
accuracy were improved by
lowest bias ratio
MDRD
eliminating the Black race
and best accuracy with/without race coefficient
for this population coefficient
The MDRD also performed
better without the race
CKD-EPI
coefficient
with/without race
coefficient
Aim / Objective

iGFR for direct
measurement
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Implications JHEBN
for Practice
HIV patients Level:
in Africa may III
benefit from
Quality:
using the
C
CKD-EPI
with no race
coefficient to
measure
eGFR for
their
medications
which dosages
depend on
kidney
function

Design
Author /
Year
Zelnick Prospective cohort
et al.
study
(2021)

Sample /
Settings
Self-identified
Black patients
from Chronic
Renal
Insufficiency
Cohort study
N=1658

Aim / Objective

eGFR
Equation(s)
To compare eGFR Creatinine based
CKD-EPI
with measured
GFR and evaluate with/without
race coefficient
the association
between eGFR
calculated with vs
Cystatin-C based
without a
coefficient for race CKD-EPI which
does not have a
and time to
race coefficient
eligibility for
kidney transplant.
iGFR for direct
measurement
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Key Findings

Implications JHEBN
for Practice
The CKD-EPI eGFR with Potential need Level:
III
the race
for more
coefficient overestimated flexible eGFR
iGFR by a mean of 3.1
thresholds, or Quality:
2
mL/min/1.73 m and by
use of iGFR for B
5.1mL/min/1.73m2 at
strict threshold
lower GFR levels
Race-based
The mean difference
eGFR may be
between CKD-EPI eGFR associated with
without the race
potential
coefficient and iGFR was Kidney
much smaller at transplant
1.71mL/min/1.73m2
delays
Use of eGFR race
coefficient had a 35%
higher risk of achieving an
eGFR less than 20
mL/min/1.73 m2 and a
shorter median time
to this end point of 1.9
years.
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